# FDA Approves Merck's Lipfendra, First Oral PCSK9 Inhibitor for High Cholesterol

> fda · REPORTED · 2026-07-17

On July 17, 2026, the FDA approved Merck's Lipfendra as the first oral PCSK9 inhibitor, expanding treatment options for adults with hypercholesterolemia beyond existing injectable therapies. This marks a significant milestone in cardiovascular lipid management.

About Merck: Merck is a global pharmaceutical company that develops and commercializes medicines across multiple therapeutic areas including cardiovascular disease, oncology, infectious diseases, and vaccines.

- Company: Merck
- Sector: cardiology
- Primary source: https://lifesciencedaily.news/weekly-news-roundup-03-august-2026/

---
Source: MedFuel Intel news monitor. Verification tier: REPORTED. Informational only, not investment advice. Corrections: media@medfuelinc.com.